infantile bronchial asthma
Conditions
Interventions
Hokunalin tape 0.5 mg is applied on chest, back, or upper arm at 8 pm once daily.
Sponsors
Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: i.Patients who present with respiratory symptom and have suspected bronchial asthma. ii.Patients who have not had a major attack of bronchial asthma during one week prior to initiation of study drug.
Exclusion criteria
Exclusion criteria: i.Patients receiving an inhaled long-acting beta-2 agonist (inhaled salmeterol) or receiving an oral short-acting beta-2 agonist continuously. ii.Patients who have known hypersensitivity to Tulobuterol Patch or have a skin disease, including atopic dermatitis, and are considered inappropriate to use Tulobuterol Patch. iii.Patients who have thyroid hyperfunction disorders, hypertension, cardiac disorder, or diabetes concurrently, and are considered inappropriate to use a beta-2 antagonist. iv.Patients who have experienced serious adverse drug reactions of Tulobuterol. v.Patients who, in the opinion of the investigator are inappropriate for inclusion in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SpO2 that will be measured using pulse oximetry for at least three hours around 4 am while the patient is sleeping | — |
Countries
Japan
Contacts
Public ContactTakahide Teramoto
Graduate School of Medicine Pediatrics
Outcome results
None listed